Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TQB 2618

Next Previous
Search
Drug Profile

TQB 2618

Alternative Names: TQB-2618

Latest Information Update: 05 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chia Tai Tianqing Pharmaceutical Group
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; HAVCR2 protein inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Nasopharyngeal cancer
  • Phase I/II Lymphoma; Squamous cell cancer
  • Phase I Acute myeloid leukaemia; Colorectal cancer; Liver cancer; Myelodysplastic syndromes; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 07 Sep 2024 Interim adverse events and efficacy data from a phase-Ib trial in Non-small cell lung cancer presented at the World Conference on Lung Cancer (WCLC-2024), ,
  • 01 Sep 2024 Phase-I clinical trials in Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease) in China (Parenteral) prior to September 2024 ,
  • 13 Jun 2024 Efficacy and adverse event data from a phase I/II trial in Lymphoma presented at the 29th Congress of the European Haematology Association (EHA-2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top